Could Gut Bacteria Be Triggering Lupus Flares?

New research published in The Annals of Rheumatic Disease highlights an important link between the gut microbiome and lupus nephritis, a serious condition where lupus affects the kidneys. Scientists have long suspected that gut bacteria may influence autoimmune diseases, and this study takes a closer look at a specific bacterium (Ruminococcus gnavus) that appears to play a role in disease flares.

“Our study provides the foundational evidence that detection of antilipoglycan antibodies from Ruminococcus gnavus blooms in the gut could identify those people at increased risk of lupus nephritis,” said study senior investigator Gregg Silverman, M.D., an immunologist and professor of internal medicine at the NYU Grossman School of Medicine.

What Investigators Found

In patients with lupus nephritis, higher levels of Ruminococcus gnavus in the gut were linked to increased immune system activity. Specifically, the team observed heightened activation of immune cells involved in inflammation and blood clotting. This suggests that changes in gut bacteria may not just be a side effect of disease, but could actively contribute to worsening symptoms.

A key discovery was that certain strains of this bacterium produce a toxin-like substance called a lipoglycan. The body can develop antibodies against this substance, and patients with higher levels of these antibodies showed more signs of inflammation. These included markers tied to immune overactivity and processes that can damage blood vessels and organs.

Key Takeaways

• Higher levels of Ruminococcus gnavus were linked to increased immune activation.
• Antibodies to the bacterial lipoglycan were associated with more inflammation.
• These antibodies may serve as a potential biomarker to identify patients at higher risk of flares.

“Our research reshapes our fundamental understanding of lupus nephritis, supporting our underlying theory that gut microbiome imbalances drive the disease, leading to Ruminococcus gnavus growths, which in turn produce the immune reactions and inflammation tied to long-term renal damage,” said Silverman.

To better understand how this works, the team tested the theory in mice. When mice were exposed to the bacteria (or just the toxin it produces) they developed immune responses similar to those seen in lupus nephritis. This included inflammation, activation of blood components like platelets and kidney injury.

“Our findings also set the stage for using selective antibiotic drugs to block these bacterial growths, or other inhibiting drugs to block the toll-like receptor 2 toxins produced by these bacterial blooms, to treat lupus nephritis,” said Silverman.

What this means:

• The bacterium and its toxin may directly trigger harmful immune responses.
• These responses can lead to inflammation and organ damage, including in the kidneys.

Why This Matters for Patients

This study points to a previously unrecognized subtype of lupus nephritis, where disease flares may be driven by gut bacteria and the immune system’s reaction to them. It reinforces the idea that lupus is influenced by more than just genetics — it may also be shaped by what’s happening in the gut.

For patients, this could lead to meaningful advances in care:

• Earlier detection of flares: Blood tests measuring antibodies to the bacterial toxin could help identify risk sooner.
• More personalized treatments: Future therapies might target specific gut bacteria or the immune pathways they trigger.
• A broader view of disease management: Gut health may become an important part of managing lupus.

“Our findings also set the stage for using selective antibiotic drugs to block these bacterial growths, or other inhibiting drugs to block the toll-like receptor 2 toxins produced by these bacterial blooms, to treat lupus nephritis,” said Silverman.

This research adds to growing evidence that the gut microbiome plays a powerful role in autoimmune diseases like lupus. By identifying how specific bacteria may trigger inflammation, scientists are moving closer to more targeted, personalized approaches to care — offering hope for better prevention and treatment of lupus nephritis flares.

“These results lay the groundwork for demonstrating how clinicians could diagnose and potentially treat lupus nephritis patients earlier and more effectively than before,” concluded Silverman.